Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.75 +0.49 (+4.00%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

21 22 Next >

Earnings Scheduled For February 22, 2024 ↗

February 22, 2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.

Via Benzinga

A Preview Of Intellia Therapeutics's Earnings ↗

February 21, 2024

Via Benzinga

Is It Too Late to Buy Intellia Therapeutics Stock? ↗

January 27, 2024

2024 could be an important year for the biotech.

Via The Motley Fool

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought ↗

February 20, 2024

These exciting players could deliver explosive growth over time.

Via The Motley Fool

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential ↗

February 19, 2024

Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.

Via InvestorPlace

Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen? ↗

February 17, 2024

Good news may be on the way, but it will be a while before it arrives.

Via The Motley Fool

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

February 15, 2024

From ReCode Therapeutics

Via Business Wire

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

3 Gene Editing Stocks With Unprecedented Surge Potential ↗

February 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

Via InvestorPlace

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

February 07, 2024

The widely followed growth investor keeps making moves.

Via The Motley Fool

Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock ↗

February 05, 2024

Via Benzinga

A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist ↗

February 05, 2024

These biotech innovators have what it takes to soar.

Via The Motley Fool

Cathie Wood's Ark Invest Snatches Up $4.7M More In Tesla Shares, Invests Equally In This Rocket Company ↗

February 01, 2024

Via Benzinga

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential ↗

January 31, 2024

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example.

Via InvestorPlace

History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. ↗

January 30, 2024

Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.

Via The Motley Fool

Topics Stocks

2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street ↗

January 27, 2024

Expectations for these stocks are sky-high, but so are the risks.

Via The Motley Fool

3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024 ↗

January 22, 2024

Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune.

Via InvestorPlace

Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics ↗

January 21, 2024

Both companies are going to continue doing high-impact science in 2024.

Via The Motley Fool

The Top Healthcare Stocks to Buy With $100 ↗

January 13, 2024

These companies are shaping the healthcare of tomorrow.

Via The Motley Fool

Voyager Therapeutics stock pops 30% on deal with Novartis

January 08, 2024

Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took

Via MarketBeat

Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics ↗

January 08, 2024

These two are at very different stages of the clinical trials process.

Via The Motley Fool

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 ↗

January 08, 2024

Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.

Via The Motley Fool

AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts ↗

January 05, 2024

AlloVir layoffs are coming for 95% of the company's employees as a way to reduce costs and preserve cash after failed clinical trials.

Via InvestorPlace

Topics Workforce

Why Is Medical Properties Trust (MPW) Stock Down 31% Today? ↗

January 05, 2024

Medical Properties Trust stock is falling hard on Friday as investors in MPW react to a rent repayment plan with Steward Health Care System.

Via InvestorPlace

Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts ↗

January 05, 2024

Intellia Therapeutics layoffs are in the news on Friday as the biotech company prepares to cut its total workforce by 15% to reduce costs.

Via InvestorPlace

Topics Workforce

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics ↗

December 31, 2023

Curing rare inherited illnesses could be a lucrative business model.

Via The Motley Fool

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Via MarketBeat

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.